Global Markets for Generic Drugs

The global market for generic drugs is expected to grow from $435.3 billion in 2023 and projected to reach $655.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2028.

The global market for small molecule generic drugs is expected to grow from $402.6 billion in 2023 and projected to reach $554.7 billion by the end of 2028, at a CAGR of 6.6% from 2023 to 2028.

The global market for biosimilar drugs is expected to grow from $32.7 billion in 2023 and projected to reach $101.1 billion by the end of 2028, at a CAGR of 25.3% from 2023 to 2028.

Report Scope:

The report discusses the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets. The report covers small molecule drugs and biosimilars. It includes market drivers and challenges in the generic drug industry. The competitive landscape includes generic drug sales of key competitors and their ranking in the market. It also covers the emerging trends in the generic drugs industry.

By geographical region, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes countries such as the U.S., Canada and Mexico; Europe includes Germany, U.K., Italy, and Rest of Europe; Asia-Pacific includes China, India, Japan, and Rest of Asia-Pacific. The estimated values used are based on drug manufacturers' total revenues.

Report Includes:

37 data tables and 39 additional tables
An overview of the global markets for generic (pharmaceutical) drugs
Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Estimate of the market size and revenue forecast of the market for generic drugs, and corresponding market share analysis based on molecule type and geographic region
Evaluation of the current and future market potential of generic drugs, as well as the major generics, regulatory landscape and patent cliff within the biopharmaceutical industry
Discussion of the major market drivers, opportunities and challenges, emerging technologies, and regulations
Data and market value analyses for the U.S., Canada, Mexico, Germany, the U.K., Italy, China, India and Japan
Overview of the sustainability trends and factors in the market for generic drugs, with emphasis on consumer attitudes, ESG scores, case studies and the ESG practices of leading companies
Analysis of the pipeline for new generic drugs and their impact on the growth of the overall biopharmaceutical products market
Patent review and analysis of key patent grants
An analysis of the industry structure, including company market shares, recent M&A activity, and venture funding
Analysis of the top market players, their global rankings, recent developments, key financials and segmental revenues, and product portfolios
Profiles of the leading market players

Product Code: PHM009K

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in this Update?
Research Methodology
Information Sources
Regional Breakdown
Segmentation Breakdown

Chapter 2 Summary and Highlights

Market Outlook
Market Summary

Chapter 3 Market Overview

Introduction
Adequate Market Size
Patent-Expired Therapies
Older Products Still Used
Long-Term Use
Straightforward Production Technology
Drugs Used in Primary Care
Biosimilars

Chapter 4 Market Dynamics

Market Drivers
Increasing Patent Cliffs and Loss of Exclusivities
Favorable Healthcare Policies
Changing Physician Attitudes
Market Challenges
Pricing Pressures and Low Profit Margins
Patent Extension Strategies of Innovator Companies

Chapter 5 Market Breakdown by Molecule Type

Global Market for Generic Drugs
Global Generic Drugs Market, by Molecule Type
Small Molecule Generics
Biosimilars

Chapter 6 Market Breakdown by Region

Introduction
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Chapter 7 Sustainability: An ESG Perspective

Introduction to ESG
Sustainability in the Generic Drugs Industry: An ESG Perspective
Key ESG Issues
Environmental Performance of Key Generic Drug Companies
Social Performance of Key Generic Drug Companies
Governance Performance of Key Generic Drug Companies
Case Study
Concluding Remarks from BCC

Chapter 8 Emerging Trends and Developments

Key Trends in the Market
Collaborations for R&D
Rise of Complex Generics in Immunology and Oncology
Improving Portfolio Efficiency
Focus on Emerging Markets

Chapter 9 Regulatory Landscape

Regulatory Overview
U.S.
Evolving Situation in the U.S.
European Union
Japan
Regulation of Biosimilars
EU Provisions
Authorized Generic Drugs

Chapter 10 Competitive Landscape

Competitive Landscape
M&A Analysis

Chapter 11 Company Profiles

ASPEN PHARMACARE
AUROBINDO PHARMA
CIPLA INC.
DR. REDDY'S LABORATORIES LTD.
FRESENIUS KABI
LUPIN LTD.
SANDOZ
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.

Product Code: PHM009K

List of Tables

Summary Table A : Global Market for Generic Drugs, by Molecule Type, Through 2028
Summary Table B : Global Market for Generic Drugs, by Region, Through 2028
Table 1 : List of Block Buster Drugs Undergoing Patent Expiry in Coming Years
Table 2 : Global Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 3 : Global Market for Generic Drugs, by Top 10 Countries, Through 2028
Table 4 : Global Top Selling Pharmaceuticals, 2022
Table 5 : Global Market for Generic Drugs, by Molecule Type, Through 2028
Table 6 : Global Market for Small Molecule Generics, by Region, Through 2028
Table 7 : Approved Biosimilar Products in the U.S.
Table 8 : Global Market for Biosimilars, by Region, Through 2028
Table 9 : Global Market for Generic Drugs, by Region, Through 2028
Table 10 : North American Market for Generic Drugs, Through 2028
Table 11 : U.S. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 12 : Canadian Key Therapeutic Areas in Retail and Hospital Purchases, 2022
Table 13 : Canadian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 14 : European Market for Generic Drugs, by Country, Through 2028
Table 15 : German Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 16 : French Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 17 : Italian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 18 : U.K. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 19 : Spanish Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 20 : Penetration of Generic Drugs in the Pharmaceutical Market in Other European Countries, 2022
Table 21 : Rest of the European Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 22 : Asia-Pacific Market for Generic Drugs, by Country, Through 2028
Table 23 : Chinese Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 24 : Japanese Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 25 : Indian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 26 : Rest of Asia-Pacific Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 27 : RoW Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 28 : ESG Rankings for Major Generic Drugs Companies, 2023*
Table 29 : ESG: Environmental Overview
Table 30 : ESG: Social Overview
Table 31 : ESG: Governance Overview
Table 32 : Teva: ESG Ratings Received, 2022
Table 33 : Collaborations for R&D and Licensing Agreements, 2022 and 2023
Table 34 : Portfolio Expansion Activities of Key Generic Companies
Table 35 : Requirements for NDA and ANDA Applications
Table 36 : Leading Generic Drug Companies, by Sales, 2022
Table 37 : Comparative Analysis of Top Three Competitors
Table 38 : M&A Analysis of Generic Drugs Markets, 2022 and 2023
Table 39 : Aspen Pharmacare Holdings Ltd.: Company Snapshot
Table 40 : Aspen Pharmacare Holdings Ltd.: Financials, 2021 and 2022
Table 41 : Aspen Pharmacare Holdings Ltd: Key Product Portfolio
Table 42 : Aspen Pharmacare Holdings Ltd.: Recent Developments, 2023
Table 43 : Aurobindo Pharma Ltd.: Company Snapshot
Table 44 : Aurobindo Pharma Ltd.: Financials, 2021 and 2022
Table 45 : Aurobindo Pharma Ltd.: Recent Developments, 2022
Table 46 : Cipla Inc.: Company Snapshot
Table 47 : Cipla Inc.: Financials, 2021 and 2022
Table 48 : Cipla Inc.: Key Product Launches, by Region, 2022
Table 49 : Cipla Inc.: Recent Developments, 2023
Table 50 : Dr. Reddy's Laboratories Ltd.: Company Snapshot
Table 51 : Dr. Reddy's Laboratories Ltd.: Financials, 2021 and 2022
Table 52 : Dr. Reddy's Laboratories Ltd.: Biosimilars Portfolio
Table 53 : Dr. Reddy's Laboratories Ltd.: Recent Developments, 2022-2023
Table 54 : Fresenius Kabi AG: Company Snapshot
Table 55 : Fresenius Kabi AG: Biosimilars Portfolio
Table 56 : Fresenius Kabi AG: Biosimilar Products in Pipeline
Table 57 : Fresenius Kabi AG: Recent Developments, 2022-2023
Table 58 : Lupin Ltd.: Company Snapshot
Table 59 : Lupin Ltd.: Financials, 2021 and 2022
Table 60 : Lupin Ltd.: Recent Developments, 2023
Table 61 : Sandoz Group AG: Company Snapshot
Table 62 : Sandoz Group AG: Financials, 2021 and 2022
Table 63 : Sandoz Group AG: Product Portfolio
Table 64 : Sandoz Group AG: Key Biosimilar Products in Phase III and Registration
Table 65 : Sandoz Group AG: Recent Developments, 2023
Table 66 : Sun Pharmaceutical Industrial Ltd.: Company Snapshot
Table 67 : Sun Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Table 68 : Teva Pharmaceutical Industrial Ltd.: Company Snapshot
Table 69 : Teva Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Table 70 : Teva Pharmaceutical Industrial Ltd.: Biosimilars Portfolio
Table 71 : Teva Pharmaceutical Industrial Ltd.: Recent Developments, 2023
Table 72 : Viatris Inc.: Company Snapshot
Table 73 : Viatris Inc.: Financials, 2021 and 2022
Table 74 : Viatris Inc.: Recent Developments, 2022-2023

List of Figures

Summary Figure A : Global Market for Generic Drugs, by Molecule Type, 2020-2028
Summary Figure B : Global Market for Generic Drugs, by Region, 2020-2028
Figure 1 : Generic Drugs Market Dynamics
Figure 2 : Generic Drugs Approved in the U.S., 2019-2022
Figure 3 : Regulatory Pathways for Small Molecule Generics and Biosimilars
Figure 4 : Global Market Shares of Generic Drugs, by Molecule Type, 2022
Figure 5 : Global Market for Small Molecule Generics, 2020-2028
Figure 6 : Global Market for Biosimilars, 2020-2028
Figure 7 : Snapshot of Global Market for Generic Drugs, by Region
Figure 8 : Global Market Shares of Generic Drugs, by Region, 2022
Figure 9 : Annual Savings from Biosimilars and Generics in the U.S., 2019-2022
Figure 10 : European Market Shares of Generic Drugs, by Country, 2022
Figure 11 : Asia-Pacific Market Shares of Generic Drugs, by Country, 2022
Figure 12 : ESG Pillars
Figure 13 : Advantages of ESG for Companies in the Generic Drugs Market
Figure 14 : Key Focus Areas in ESG Metrics in the Generics Market
Figure 15 : Teva: ESG Indicators, 2022
Figure 16 : Emerging Trends in the Generic Drugs Market
Figure 17 : Aspen Pharmacare Holdings Ltd.: Financials, 2021 and 2022
Figure 18 : Aspen Pharmacare Holdings Ltd.: Market Share, by Business Segment, 2022
Figure 19 : Aspen Pharmacare Holdings Ltd.: Revenue Share, by Region, 2022
Figure 20 : Aurobindo Pharma Ltd.: Financials, 2021 and 2022
Figure 21 : Aurobindo Pharma Ltd.: Revenue Share, by Business Segment, 2022
Figure 22 : Aurobindo Pharma Ltd.: ANDA Filings, by Region, FY2022
Figure 23 : Cipla Inc.: Financials, 2021 and 2022
Figure 24 : Cipla Inc.: Revenue Share, by Business Segment, 2022
Figure 25 : Cipla Inc.: ANDAs Pipeline, FY 2022
Figure 26 : Dr. Reddy's Laboratories Ltd.: Financials, 2021 and 2022
Figure 27 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Business Segment, 2022
Figure 28 : Dr. Reddy's Laboratories Ltd.: Global Generics Revenue Share, by Therapeutic Area, 2022
Figure 29 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Country, 2022
Figure 30 : Lupin Ltd.: Financials, 2021 and 2022
Figure 31 : Lupin Ltd.: Revenue Share, by Business Segment, 2022
Figure 32 : Lupin Ltd.: India Revenue Share, by Therapeutic Area, 2022
Figure 33 : Timeline of Novartis and Sandoz Separation
Figure 34 : Sandoz Group AG: Financials, 2021 and 2022
Figure 35 : Sandoz Group AG: Market Share, by Business Segment, 2022
Figure 36 : Sandoz Group AG: Revenue Share, by Region, 2022
Figure 37 : Sun Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Figure 38 : Sun Pharmaceutical Industrial Ltd.: Revenue Share, by Business Segment, 2022
Figure 39 : Cumulative ANDAs Filed and Approved in the U.S., FY 2019-FY 2023
Figure 40 : Teva Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Figure 41 : Teva Pharmaceutical Industrial Ltd.: Revenue Share, by Region, 2022
Figure 42 : Viatris Inc.: Financials, 2021 and 2022
Figure 43 : Viatris Inc.: Market Share, by Business Segment, 2022
Figure 44 : Viatris Inc.: Revenue Share, by Region, 2022

Global Markets for Generic Drugs

Description

Table of Contents

List of Tables

Highlights:

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Market Dynamics

Chapter 5 Market Breakdown by Molecule Type

Chapter 6 Market Breakdown by Region

Chapter 7 Sustainability: An ESG Perspective

Chapter 8 Emerging Trends and Developments

Chapter 9 Regulatory Landscape

Chapter 10 Competitive Landscape

Chapter 11 Company Profiles

List of Tables

List of Figures